Retrieve available abstracts of 48 articles: HTML format
Single Articles
April 2025
WALKE P, Price JDW, Vizeacoumar FS, Joseph N, et al A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate
cancer.
Oncogene. 2025 Apr 29. doi: 10.1038/s41388-025-03413. PubMedAbstract available
ANDRIEU C, Taieb D, Baylot V, Ettinger S, et al Editorial Expression of Concern: Heat shock protein 27 confers resistance to
androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03407. PubMed
YANG JC, Xu P, Ning S, Wasielewski LJ, et al Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB
synergizes enzalutamide treatment in advanced prostate cancer.
Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03392. PubMed
March 2025
HOFSTAD M, Woods A, Parra K, Sychev ZE, et al Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer.
Oncogene. 2025 Mar 21. doi: 10.1038/s41388-025-03343. PubMedAbstract available
YIN L, Dai Y, Wang Y, Liu S, et al A mitochondrial outer membrane protein TOMM20 maintains protein stability of
androgen receptor and regulates AR transcriptional activity in prostate cancer
cells.
Oncogene. 2025 Mar 6. doi: 10.1038/s41388-025-03328. PubMedAbstract available
SCHMIDT MJ, Naghdloo A, Prabakar RK, Kamal M, et al Polyploid cancer cells reveal signatures of chemotherapy resistance.
Oncogene. 2025;44:439-449. PubMedAbstract available
January 2025
KAUSHAL JB, Raut P, Halder S, Alsafwani ZW, et al Oncogenic potential of truncated-Gli3 via the Gsk3beta/Gli3/AR-V7 axis in
castration-resistant prostate cancer.
Oncogene. 2025 Jan 16. doi: 10.1038/s41388-024-03266. PubMedAbstract available
December 2024
DUTTA S, Khedmatgozar H, Patel GK, Latour D, et al A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor
confers therapeutic resistance in prostate cancer.
Oncogene. 2024 Dec 20. doi: 10.1038/s41388-024-03252. PubMedAbstract available
WOYTASH JA, Kumar R, Chaudhary AK, Donnelly C, et al Mitochondrial unfolded protein response-dependent beta-catenin signaling promotes
neuroendocrine prostate cancer.
Oncogene. 2024 Dec 17. doi: 10.1038/s41388-024-03261. PubMedAbstract available
November 2024
HUANG F, Li K, Chen Z, Cui Z, et al Integrative analysis identifies the atypical repressor E2F8 as a targetable
transcriptional activator driving lethal prostate cancer.
Oncogene. 2024 Nov 29. doi: 10.1038/s41388-024-03239. PubMedAbstract available
RODRIGUES SOUSA E, de Brot S, Zoni E, Zeinali S, et al CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in
vivo, organoid, and patient data.
Oncogene. 2024 Nov 26. doi: 10.1038/s41388-024-03230. PubMedAbstract available
LYU C, Vaddi PK, Elshafae S, Pradeep A, et al Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer
development.
Oncogene. 2024 Nov 13. doi: 10.1038/s41388-024-03224. PubMedAbstract available
SHARMA S, Pei X, Xing F, Wu SY, et al Correction: Regucalcin promotes dormancy of prostate cancer.
Oncogene. 2024 Nov 11. doi: 10.1038/s41388-024-03216. PubMed
TAHSIN S, Sane NS, Cernyar B, Jiang L, et al Correction: AR loss in prostate cancer stroma mediated by NF-kappaB and p38-MAPK
signaling disrupts stromal morphogen production.
Oncogene. 2024 Nov 7. doi: 10.1038/s41388-024-03190. PubMed
OFFENHAUSER C, Dave KA, Beckett KJ, Smith FM, et al EphA2 regulates vascular permeability and prostate cancer metastasis via
modulation of cell junction protein phosphorylation.
Oncogene. 2024 Nov 7. doi: 10.1038/s41388-024-03206. PubMedAbstract available
HUANG H, Zhuang X, Yin S, Sun W, et al The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive
progression of prostate cancer.
Oncogene. 2024 Nov 2. doi: 10.1038/s41388-024-03209. PubMedAbstract available
RHEE JW, Adzavon YM, Sun Z Stromal androgen signaling governs essential niches in supporting prostate
development and tumorigenesis.
Oncogene. 2024;43:3419-3425. PubMedAbstract available
October 2024
WANG K, Chen M, Yan S, Han Y, et al Zinc ions activate AKT and promote prostate cancer cell proliferation via
disrupting AKT intramolecular interaction.
Oncogene. 2024 Oct 23. doi: 10.1038/s41388-024-03195. PubMedAbstract available
LIN G, Tian F, Yu Q, Weng X, et al IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer
growth.
Oncogene. 2024 Oct 18. doi: 10.1038/s41388-024-03169. PubMedAbstract available
XIONG X, Zhang S, Zhu W, Du J, et al Androgen-ablative therapies inducing CXCL8 regulates mTORC1/SREBP2-dependent
cholesterol biosynthesis to support progression of androgen receptor negative
prostate cancer cells.
Oncogene. 2024 Oct 5. doi: 10.1038/s41388-024-03181. PubMedAbstract available
September 2024
MU Y, Wallenius A, Zang G, Zhu S, et al The TbetaRI promotes migration and metastasis through thrombospondin 1 and ITGAV in
prostate cancer cells.
Oncogene. 2024 Sep 20. doi: 10.1038/s41388-024-03165. PubMedAbstract available
SARDAR S, McNair CM, Ravindranath L, Chand SN, et al AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate
cancer.
Oncogene. 2024 Sep 13. doi: 10.1038/s41388-024-03148. PubMedAbstract available
August 2024
YU J, Zhang M, Li T, Gao W, et al Monoacylglycerol lipase blockades the senescence-associated secretory phenotype
by interfering with NF-kappaB activation and promotes docetaxel efficacy in prostate
cancer.
Oncogene. 2024 Aug 18. doi: 10.1038/s41388-024-03132. PubMedAbstract available
XIONG S, Li S, Li Z, Song Y, et al A noncanonical E3 ubiquitin ligase RNF41-mediated MYO1C stability promotes
prostate cancer metastasis by inducing actin remodeling.
Oncogene. 2024 Aug 7. doi: 10.1038/s41388-024-03120. PubMedAbstract available
July 2024
JIN Z, Wang H, Tang R, Pan B, et al GATA2 promotes castration-resistant prostate cancer development by suppressing
IFN-beta axis-mediated antitumor immunity.
Oncogene. 2024 Jul 27. doi: 10.1038/s41388-024-03107. PubMedAbstract available
June 2024
LIN G, Zhang F, Weng X, Hong Z, et al Role of gut microbiota in the pathogenesis of castration-resistant prostate
cancer: a comprehensive study using sequencing and animal models.
Oncogene. 2024 Jun 17. doi: 10.1038/s41388-024-03073. PubMedAbstract available
CHEN B, Xu P, Yang JC, Nip C, et al Plexin D1 emerges as a novel target in the development of neural lineage
plasticity in treatment-resistant prostate cancer.
Oncogene. 2024 Jun 14. doi: 10.1038/s41388-024-03081. PubMedAbstract available
FRANCIS JC, Capper A, Rust AG, Ferro K, et al Identification of genes that promote PI3K pathway activation and prostate tumour
formation.
Oncogene. 2024;43:1824-1835. PubMedAbstract available
May 2024
ZHAO J, Shen J, Mao L, Yang T, et al Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit
ferroptosis and promote acquired chemoresistance in prostate cancer.
Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03057. PubMedAbstract available
TAHSIN S, Sane NS, Cernyar B, Jiang L, et al AR loss in prostate cancer stroma mediated by NF-kappaB and p38-MAPK signaling
disrupts stromal morphogen production.
Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03064. PubMedAbstract available
BEIER AK, Ebersbach C, Siciliano T, Scholze J, et al Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal
docetaxel-resistant prostate cancer.
Oncogene. 2024 May 15. doi: 10.1038/s41388-024-03059. PubMedAbstract available
April 2024
RAWAT C, Heemers HV Alternative splicing in prostate cancer progression and therapeutic resistance.
Oncogene. 2024 Apr 24. doi: 10.1038/s41388-024-03036. PubMedAbstract available
ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al Correction: In vivo genome-wide CRISPR screening identifies CITED2 as a driver of
prostate cancer bone metastasis.
Oncogene. 2024 Apr 16. doi: 10.1038/s41388-024-03031. PubMed
LI Y, Lv L, Ye M, Xie N, et al PDIA2 has a dual function in promoting androgen deprivation therapy induced
venous thrombosis events and castrate resistant prostate cancer progression.
Oncogene. 2024 Apr 8. doi: 10.1038/s41388-024-03024. PubMedAbstract available
CHEN M, Zou C, Tian Y, Li W, et al An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a
tumor suppressive role in aggressive prostate cancer.
Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03011. PubMedAbstract available
March 2024
YI Q, Han X, Yu HG, Chen HY, et al SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by
targeting the androgen receptor N-terminal domain.
Oncogene. 2024 Mar 26. doi: 10.1038/s41388-024-02944. PubMedAbstract available
GUO S, Miao M, Wu Y, Pan D, et al DHODH inhibition represents a therapeutic strategy and improves abiraterone
treatment in castration-resistant prostate cancer.
Oncogene. 2024 Mar 13. doi: 10.1038/s41388-024-03005. PubMedAbstract available
ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate
cancer bone metastasis.
Oncogene. 2024 Mar 7. doi: 10.1038/s41388-024-02995. PubMedAbstract available
LI J, Hong Z, Zhang J, Zheng S, et al Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate
CRPC cell resistance to enzalutamide.
Oncogene. 2024;43:744-757. PubMedAbstract available
January 2024
CHAO Y, Chen Y, Zheng W, Demanelis K, et al Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of
castration-resistant prostate cancer.
Oncogene. 2024 Jan 25. doi: 10.1038/s41388-024-02939. PubMedAbstract available
RODRIGUEZ TIRADO C, Wang C, Li X, Deng S, et al UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor
degradation and antiandrogen resistance.
Oncogene. 2024;43:265-280. PubMedAbstract available
December 2023
FERRARI MG, Jimenez-Uribe AP, Wang L, Hoeppner LH, et al Myeloid differentiation factor-2/LY96, a potential predictive biomarker of
metastasis and poor outcomes in prostate cancer: clinical implications as a
potential therapeutic target.
Oncogene. 2023 Dec 23. doi: 10.1038/s41388-023-02925. PubMedAbstract available
MILLER KA, Degan S, Wang Y, Cohen J, et al Correction: PTEN-regulated PI3K-p110 and AKT isoform plasticity controls
metastatic prostate cancer progression.
Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02920. PubMed
CHAUHAN SS, Casillas AL, Vizzerra AD, Liou H, et al PIM1 drives lipid droplet accumulation to promote proliferation and survival in
prostate cancer.
Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02914. PubMedAbstract available
November 2023
EIGENTLER A, Handle F, Schanung S, Degen A, et al Glucocorticoid treatment influences prostate cancer cell growth and the tumor
microenvironment via altered glucocorticoid receptor signaling in prostate
fibroblasts.
Oncogene. 2023 Nov 29. doi: 10.1038/s41388-023-02901. PubMedAbstract available
CUI H, Wang Y, Zhou T, Qu L, et al Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux
blockage via oxidative stress.
Oncogene. 2023 Nov 16. doi: 10.1038/s41388-023-02878. PubMedAbstract available
October 2023
MILLER KA, Degan S, Wang Y, Cohen J, et al PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate
cancer progression.
Oncogene. 2023 Oct 24. doi: 10.1038/s41388-023-02875. PubMedAbstract available
September 2023
ADVANI R, Luzzi S, Scott E, Dalgliesh C, et al Epithelial specific splicing regulator proteins as emerging oncogenes in
aggressive prostate cancer.
Oncogene. 2023 Sep 26. doi: 10.1038/s41388-023-02838. PubMedAbstract available